Key result
A fixed dose of isosorbide dinitrate plus hydralazine significantly improved the primary composite score (-0.1 vs -0.5; P=0.01) and reduced mortality (6.2% vs 10.2%; P=0.02) compared to placebo.
Why the study?
Does a fixed dose of isosorbide dinitrate plus hydralazine improve a composite score of death, heart failure hospitalization, and quality of life in black patients with advanced heart failure?
Population
1050 black patients with New York Heart Association class III or IV heart failure with dilated ventricles
Comparison
Fixed dose of isosorbide dinitrate plus… vs Placebo in addition to standard therapy for…
Design
RCT, randomly assigned
Authors
Loading...
Supports addition of isosorbide dinitrate-hydralazine to standard therapy in black patients with NYHA III-IV HF; confirms benefit on composite outcomes and mortality.
RCT (n=1,050)
Does a fixed dose of isosorbide dinitrate plus hydralazine improve a composite score of death, heart failure hospitalization, and quality of life in black patients with advanced heart failure?
Absolute Event Rate: -0.1% vs -0.5%
p-value: p=0.01
The addition of a fixed dose of isosorbide dinitrate and hydralazine to standard therapy significantly improves survival and reduces hospitalizations in black patients with advanced heart failure.
Virk et al. (2005) conducted an RCT in advanced heart failure (n=1,050). isosorbide dinitrate plus hydralazine vs. placebo was evaluated on composite score made up of weighted values for death from any cause, a first hospitalization for HF, and change in the quality of life (p=0.01). A fixed dose of isosorbide dinitrate plus hydralazine significantly improved the primary composite score (-0.1 vs -0.5; P=0.01) and reduced mortality (6.2% vs 10.2%; P=0.02) compared to placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: